Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology • Cholangiocarcinoma • Journal Club ft. NEJM publications
Would you consider PD-L1 score when deciding whether to incorporate durvalumab in first-line metastatic biliary cancer?
If so, what assay would you use in this population?
Do we have data on TMB/PDL1 status of long-term survivors?
Answer from: Medical Oncologist at Community Practice
There are no biomarkers that I currently recommend to select patients for durvalumab in first-line metastatic biliary cancer. In subgroup analysis, there appears to be benefit to durvalumab in first-line metastatic biliary tract cancer regardless of PDL1 expression. Therefore, I would not consider P...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I do not, no clear benefit shown based on PDL1 status.